REGN Earnings & Financial Statements
Regeneron Pharmaceuticals, Inc.
$805.10
+$26.74(+3.44%)
59
Overall
80
Value
40
Tech
57
Quality
Market Cap
$80.14B
Volume
390.09K
52W Range
$541.00 - $859.34
Target Price
$861.62
REGN earnings and financial statements: Regeneron Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
REGN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Cost of revenue | $2.10B | $1.97B | $1.82B | $1.56B | $2.44B |
| Operating income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B |
| EBITDA | $5.82B | $5.32B | $4.69B | $5.26B | $9.67B |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| EPS (diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B |
| Shareholders’ equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B |
| Cash and equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B |
| Long-term debt | $2.71B | $2.70B | $2.70B | $2.70B | $1.98B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B |
| Capital expenditure | -$898.40M | -$735.80M | -$926.40M | -$1.62B | -$551.90M |
| Free cash flow | $4.08B | $3.66B | $3.88B | $3.40B | $6.53B |
| Dividends paid | $370.30M | - | - | - | - |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | REGN | $805.10 | +3.4% | 390.09K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Regeneron Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW